Stan Mychailo Petrovych M. Peculiar features of the course of gastroesophageal reflux disease and its management in patients with carbon and lipid metabolism disorders

The combination of background therapy with ursodeoxycholic acid and Rebamipide proved to be more effective than the background therapy itself both in the patients with the combined disorders and in the patients with GERD without the accompanying disorders. The findings of the data analysis also demonstrate the evident positive effect of the administered therapy on the endoscopic changes in the patients of both groups. After administering the combination therapy that involved ursodeoxycholic acid and Rebamipide the number of patients with LA-A increased to 40,0% among the patients in Group I and to 35,1% among the patients in Group II (р<0,01). The combination therapy that used high-dose ursodeoxycholic acid in addition to dietary advice and lifestyle modification had a positive impact on BMI dynamics. BMI reduction was accompanied by a tendency towards the normalization of carbohydrate metabolism parameters in Group II patients, in particular the insulin level was found to decrease to 14,77±1,15 U/L, C-Peptide level to 8,75±0,39 ng/ml and HOMA-IR to 4,14±0,96 (р<0,01) against the background of the combination therapy involving the use of ursodeoxycholic acid and Rebamipide. The suggested combination therapy against the background of lifestyle modification and dietary advice had a positive effect on the lipid metabolism parameters in the patients included in the study. The study demonstrated the feasibility of using ursodeoxycholic acid and Rebamipide in order to prevent the progression of damage to the esophagus, to reduce body weight, to restore metabolism and normalize the prostacyclin and prostaglandin I2 markers in blood serum against the background of lifestyle modification in patients with GERD and carbon and lipid metabolism disorders.